KPRX实时信号 | 通过Getagraph.com最大化利润

购买 123043 min ago

@ $0.800

发出时间: 8 Feb 2024 @ 02:05

回报率: -32.18%

上一信号: Feb 8 - 00:44

上一信号: 出售

回报率: -5.88 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States...

Stats
今日成交量	53 021.00
平均成交量	356 283
市值	14.25M
EPS	$-0.470 ( 2024-03-28 )
下一个收益日期	( $-0.420 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.200
ATR14	$0.00800 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-29	Tosca Melissa	Buy	60 000	Stock Option (right to buy)
2023-09-29	Tosca Melissa	Buy	30 000	Common Stock
2023-09-29	Daniels Eric Joseph	Buy	125 000	Stock Option (right to buy)
2023-09-29	Daniels Eric Joseph	Buy	62 500	Common Stock
2023-09-29	Strem Brian M.	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 1 933 640 \| Sell: 3 426 001

Kiora Pharmaceuticals, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kiora Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2023
营收:	$0
毛利润:	$-62 424.00 (0.00 %)
EPS:	$-2.58

FY	2022
营收:	$0
毛利润:	$-134 028 (0.00 %)
EPS:	$-18.55

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-143.31

Financial Reports:

No articles found.

Kiora Pharmaceuticals,

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

实时更新： Kiora Pharmaceuticals, [KPRX]

Upcoming Earnings Alert